Article type
Year
Abstract
Background:
On March 11, 2020, the World Health Organization (WHO) said that the COVID-19 outbreak can be characterized as a "pandemic" as the "SARS-COV-2" virus spreads increasingly worldwide. Following the outbreak of COVID-19, China and even the world have started a number of COVID-19 clinical trials in order to verify the effectiveness and safety of various diagnosis and treatment measures.
Objectives:
To survey the registration of COVID-19 clinical trial and analysis their characteristics.
Methods:
We will systematically search the following four clinical trial registry platforms up to March 25, 2020: the World Health Organization Clinical Trials Registry Platform (http://www.who.int/ictrp/en/), the International Standard Randomized Controlled Trial Number(ISRCTN) Register (https://www.isrctn.com/), the US National Institutes of Health Trials Register (https://clinicaltrials.gov/) and the Chinese Clinical Trial Registry (http://www.chictr.org.cn/index.aspx) to identify all COVID-19 clinical trials. After selection, we will extract the basic characteristics and perform descriptive statistics: the study setting and funding, sample size, study design, intervention, indication, primary outcome and so on. If the trial is focusing on the effects of drugs, we will also identify the type of drugs. If the trial is a randomized controlled trial, we will also identify the type of blinding. The search, selection and extraction will be conducted by two researchers independently and the discrepancies will be resolved by discussion and consensus to a third researcher.
Results:
This survey is ongoing and results will be presented at the Cochrane Colloquium as available.
Conclusions:
This survey is ongoing and conclusions will be presented at the Cochrane Colloquium as available.
Patient or healthcare consumer involvement:
None
On March 11, 2020, the World Health Organization (WHO) said that the COVID-19 outbreak can be characterized as a "pandemic" as the "SARS-COV-2" virus spreads increasingly worldwide. Following the outbreak of COVID-19, China and even the world have started a number of COVID-19 clinical trials in order to verify the effectiveness and safety of various diagnosis and treatment measures.
Objectives:
To survey the registration of COVID-19 clinical trial and analysis their characteristics.
Methods:
We will systematically search the following four clinical trial registry platforms up to March 25, 2020: the World Health Organization Clinical Trials Registry Platform (http://www.who.int/ictrp/en/), the International Standard Randomized Controlled Trial Number(ISRCTN) Register (https://www.isrctn.com/), the US National Institutes of Health Trials Register (https://clinicaltrials.gov/) and the Chinese Clinical Trial Registry (http://www.chictr.org.cn/index.aspx) to identify all COVID-19 clinical trials. After selection, we will extract the basic characteristics and perform descriptive statistics: the study setting and funding, sample size, study design, intervention, indication, primary outcome and so on. If the trial is focusing on the effects of drugs, we will also identify the type of drugs. If the trial is a randomized controlled trial, we will also identify the type of blinding. The search, selection and extraction will be conducted by two researchers independently and the discrepancies will be resolved by discussion and consensus to a third researcher.
Results:
This survey is ongoing and results will be presented at the Cochrane Colloquium as available.
Conclusions:
This survey is ongoing and conclusions will be presented at the Cochrane Colloquium as available.
Patient or healthcare consumer involvement:
None